Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Medical Physics|January 1, 2017
Multicenter validation of prostate tumor localization using multiparametric MRI and prior knowledgeCuong Viet Dinh, Peter Steenbergen, Ghazaleh Ghobadi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 13, 2023
From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trialLisa De Cock, Cédric Draulans, Floris J Pos, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 7, 2020
Optimal <sup>68</sup>Ga-PSMA and <sup>18</sup>F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancerCédric Draulans, Robin De Roover, Uulke A van der Heide, et al.
International Journal of Radiation Oncology, Biology, Physics|September 19, 2023
Risk Modeling for Individualization of the FLAME Focal Boost Approach in External Beam Radiation Therapy for Patients With Localized Prostate CancerKarolína Menne Guricová, Veerle Groen, Floris Pos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 3, 2024
Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trialCédric Draulans, Karin Haustermans, Floris J Pos, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 17, 2018
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trialEvelyn M Monninkhof, Juliette W L van Loon, Marco van Vulpen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 5, 2020
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancerCédric Draulans, Uulke A van der Heide, Karin Haustermans, et al.
Pageof 5